Key result
Ibrutinib is linked to reversible new-onset nonischemic cardiomyopathy and ventricular tachycardia.
Why the study?
Does ibrutinib cause cardiomyopathy and ventricular arrhythmia in patients with mantle cell lymphoma?
Case Report (n=1)
No
Does ibrutinib cause cardiomyopathy and ventricular arrhythmia in patients with mantle cell lymphoma?
This case provides the first clinical evidence linking ibrutinib to nonischemic cardiomyopathy and ventricular arrhythmias, highlighting the need for cardiac surveillance.
Answers are grounded in this paper and cite their sources.
May support cardiac surveillance during ibrutinib use; hypothesis-generating case report requiring prospective confirmation.
Ibrutinib is a first-in-class inhibitor of Bruton's tyrosine kinase, which is approved for use in chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. Although ibrutinib has been linked to an increased incidence of atrial fibrillation, this is the first report of an association with nonischemic cardiomyopathy and ventricular arrhythmia.
No takes yet. Share an insight, caveat, or question.
Wallace et al. (2016) conducted a case report in Relapsed mantle cell lymphoma (n=1). Ibrutinib was evaluated. Ibrutinib therapy was associated with the development of new-onset nonischemic cardiomyopathy and ventricular tachycardia, which improved upon discontinuation of the drug.
Synapse has enriched 10 related papers. Consider them for comparative context: